Literature DB >> 22714606

Diffuse alveolar haemorrhage may be associated with intravitreal injection of bevacizumab in a patient with systemic risk factors.

Ruriko Seto1, Hideto Yamada, Hiroshi Wada, Makoto Osawa, Taishi Nagao, Yasutaka Nakano.   

Abstract

The authors present a rare case where acute respiratory failure occurred after the intravitreal bevacizumab injection for a branch retinal vein occlusion. Chest CT scan showed ground-glass opacity in the bilateral lung fields. The finding of bronchoalveolar lavage fluid revealed alveolar haemorrhage. Corticosteroid therapy resulted in a rapid improvement of respiratory failure. This report suggests that intravitreal injection of bevacizumab may be associated with diffuse alveolar haemorrhage and acute lung injury.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22714606      PMCID: PMC3062342          DOI: 10.1136/bcr.08.2010.3224

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  19 in total

1.  Cigarette smoking, alcohol consumption, and risk of ARDS: a 15-year cohort study in a managed care setting.

Authors:  C Iribarren; D R Jacobs; S Sidney; M D Gross; M D Eisner
Journal:  Chest       Date:  2000-01       Impact factor: 9.410

2.  Acute lung injury associated with docetaxel and bevacizumab.

Authors:  A Prat; P Martínez; C Serrano; M A Montero; J Andreu; J Cortés
Journal:  Clin Oncol (R Coll Radiol)       Date:  2007-09-21       Impact factor: 4.126

3.  Bevacizumab, bleeding, thrombosis, and warfarin.

Authors:  Saadettin Kilickap; Huseyin Abali; Ismail Celik
Journal:  J Clin Oncol       Date:  2003-09-15       Impact factor: 44.544

4.  Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer.

Authors:  M S Gordon; K Margolin; M Talpaz; G W Sledge; E Holmgren; R Benjamin; S Stalter; S Shak; D Adelman
Journal:  J Clin Oncol       Date:  2001-02-01       Impact factor: 44.544

Review 5.  Vascular endothelial growth factor (VEGF) in acute lung injury (ALI) and acute respiratory distress syndrome (ARDS): paradox or paradigm?

Authors:  A R L Medford; A B Millar
Journal:  Thorax       Date:  2006-07       Impact factor: 9.139

6.  A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer.

Authors:  James C Yang; Leah Haworth; Richard M Sherry; Patrick Hwu; Douglas J Schwartzentruber; Suzanne L Topalian; Seth M Steinberg; Helen X Chen; Steven A Rosenberg
Journal:  N Engl J Med       Date:  2003-07-31       Impact factor: 91.245

7.  Pharmacokinetics of bevacizumab and its effect on vascular endothelial growth factor after intravitreal injection of bevacizumab in macaque eyes.

Authors:  Taichiro Miyake; Osamu Sawada; Masashi Kakinoki; Tomoko Sawada; Hajime Kawamura; Kazumasa Ogasawara; Masahito Ohji
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-10-29       Impact factor: 4.799

Review 8.  Diffuse alveolar hemorrhage: diagnosing it and finding the cause.

Authors:  Octavian C Ioachimescu; James K Stoller
Journal:  Cleve Clin J Med       Date:  2008-04       Impact factor: 2.321

9.  Safety and efficacy of intravitreal bevacizumab (avastin) for the management of branch and hemiretinal vein occlusion.

Authors:  Ninel Z Gregori; Ginger Henson Rattan; Philip J Rosenfeld; Carmen A Puliafito; William Feuer; Harry W Flynn; Audina M Berrocal; Luma Al-Attar; Sander Dubovy; William E Smiddy; Stephen G Schwartz; Wen-Hsiang Lee; Timothy G Murray
Journal:  Retina       Date:  2009 Jul-Aug       Impact factor: 4.256

10.  Intraocular concentrations of growth factors and cytokines in retinal vein occlusion and the effect of therapy with bevacizumab.

Authors:  Marion Funk; Katharina Kriechbaum; Franz Prager; Thomas Benesch; Michael Georgopoulos; Gerhard J Zlabinger; Ursula Schmidt-Erfurth
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-12-05       Impact factor: 4.799

View more
  2 in total

1.  Ocular Versus Oral Propranolol for Prevention and/or Treatment of Oxygen-Induced Retinopathy in a Rat Model.

Authors:  Areej Qadri; Charles L Cai; Karen Deslouches; Faisal Siddiqui; Jacob V Aranda; Kay D Beharry
Journal:  J Ocul Pharmacol Ther       Date:  2021-02-03       Impact factor: 2.671

2.  Alveolar Hemorrhage Caused by the Combination of Immune Checkpoint Inhibitors (ICIs) and Angiogenesis Inhibitors: The Underlying Long-Term Vascular Endothelial Growth Factor (VEGF) Inhibition.

Authors:  Naoki Shijubou; Takeyuki Sawai; Taku Hatakeyama; Satoru Munakata; Masami Yamazoe
Journal:  Cureus       Date:  2022-03-17
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.